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Cancer  Antigen  15-3  (CA  15-3)  and  the  extracellular  domain  of the  human  epidermal  growth  factor
receptor  2 (HER2-ECD)  are independent  breast  cancer  biomarkers.  The  combination  of  their profiles
(presence  and concentration)  could  provide  an  important  contribution  to diagnostics  and  patient  follow-
up.  Therefore,  a  disposable  electrochemical  immunosensor  for  the  simultaneous  detection  of CA  15-3
and  HER2-ECD  was developed  in  this  work.  The  immunosensor  was  constructed  on  a  customized  dual
screen-printed  carbon  electrode.  The  carbon  working  electrodes’  surfaces  were  first  modified  with  in situ
electrodeposited  gold  nanoparticles  and  then  individually  coated  with  either  a monoclonal  anti-human
CA  15-3  or a  monoclonal  anti-human  HER2-ECD  antibody.  After  incubation  with  the  biomarkers  and
monoclonal  biotin-labelled  detection  antibodies,  the  antigen-antibody  interactions  were  detected  by
linear  sweep  voltammetric  analysis  of  enzymatically  (alkaline  phosphatase)  generated  metallic  silver.
The  immunosensor’s  limits  of detection  for  the  selected  biomarkers  were  5.0  U mL−1 for  CA 15-3 and
2.9  ng mL−1 for HER2-ECD.  These  values  could  allow  the  use  of  the sensor  in  the  non-invasive  control  of
these  biomarkers  in  breast  cancer  patients.. Introduction
Breast cancer is the top cancer in women both in the devel-
ped and the developing world [1]. Screening programs and the
mprovement in treatment and follow-up have been able to lower
he mortality in the past few years [2]. However, breast cancer is
till the most common cause of cancer-related mortality in women
n less developed regions, and the second most common (after lung
ancer) in developed regions [1].
Imagiology has been a helpful tool for screening in breast cancer,
ut it is very imprecise in the prediction of the biological behavior
f the tumor. Therefore, important research has been conducted
o identify suitable biomarkers, which has led to advances in its
etection and treatment [3,4]. A cancer biomarker is a biologi-
al molecule found in tissues, cells or body fluids which presence
nd/or concentration level can be related to the presence of cancer
∗ Corresponding author.
E-mail address: han@isep.ipp.pt (H.P.A. Nouws).[5,6]. Biomarker detection may  be used for early diagnosis, staging
of disease and monitoring of the response to treatment [3,7]. Breast
cancer biomarkers include tissue markers such as estrogen and
progesterone receptors and the human epidermal growth factor
receptor 2 (HER2), and circulating markers such as carcinoembry-
onic antigen (CEA) and cancer antigen 15-3 (CA15-3) [7–9].
Although  there are many newly suggested circulating breast
cancer biomarkers, very few have been adopted into the clinic. So
far, only the detection of CA 15-3 has been routinely adopted in
practice. CA 15-3 is the shed form of MUC-1, a protein whose nor-
mal function is cell protection and lubrication, but is typically seen
to be overexpressed on breast tumor cells. CA 15-3 is therefore
considered a circulating cancer biomarker that can be detected in
serum [9,10]. Elevated levels of CA 15-3 are found in the majority
of breast cancer patients with distant metastasis; about 60–75% of
women with invasive breast cancer (metastasized cancer) present
elevated levels of CA 15-3 [10,11]. High levels of CA 15-3 may  also
be found in patients that suffer several different types of advanced
adenocarcinoma, such as ovarian, pancreatic, gastric or lung can-
cer [11]. Because CA 15-3 levels are only elevated in 10% of patients
w
H
v
m
A
v
t
o
a
e
c
m
[
r
H
t
s
b
n
n
e
i
F
b
d
o
f
(
m
i
c
o
n
m
c
A
i
o
r
k
1
p
i
E
c
r
t
e
t
b
i
a
d
b
e
s
p
i
b
t
T
a
aith stage 1 breast cancer, it has little value in early detection.
owever, CA 15-3 has been routinely adopted in practice to pro-
ide prognostic information, which is essential for optimum disease
anagement, and also as a potential predictor of treatment [6,11].
 CA 15-3 concentration of 25 U mL−1 is  considered a threshold
alue [7,10].
HER2  is a transmembrane protein of the epidermal growth fac-
or receptors family that is overexpressed in approximately 15–30%
f breast cancers [9,12]. HER2 overexpression has been related with
ccelerated growth, recurrence date, progressive metastatic dis-
ase and poor rate of disease-free survival [13,14]. This protein
onsists of three domains: an extracellular domain (ECD), a trans-
embrane domain and an intracellular tyrosine kinase domain
15]. The extracellular domain fragment of HER2 (HER2-ECD) is
eleased from the surface of tumor cells into the blood stream. Thus,
ER2-ECD levels are measurable in the serum fraction of blood and,
herefore, HER2-ECD is a minimal-invasive (since it avoids HER2
tatus tests in tissues obtained by biopsy) and clinically relevant
iomarker for breast cancer [12,13]. HER2 status characterization is
ow mandatory in breast cancer since, besides an important prog-
ostic factor, it is also a target for specific immunotherapies [16]: for
xample, the use of Trastuzumab, which is a recombinant human-
zed monoclonal antibody against HER2-ECD, was approved by the
ood and Drug Administration (FDA) in 1998 to treat metastatic
reast cancer [13,15]. Therefore, the major advantage of HER2-ECD
etermination in serum is the possibility of patient follow-up with-
ut the need of biopsies, as required by the established methods
or the assessment of HER2 status (such as immunohistochemistry
IHC)  and fluorescent in situ hybridization (FISH)) [8,12]. The nor-
al  serum HER2-ECD concentration is 15 ng mL−1 but a moderate
ncrease (50 ng mL−1) has also been described in the absence of
ancer [12,13].
In  the clinical field, determination of a single tumor marker
ften has limited diagnostic value because most biomarkers are
ot specific of a particular cancer. Moreover, most cancers have
ore than one associated biomarker. So, multi-biomarker analysis
an be essential for the early diagnosis of disease onset [17,18].
s mentioned before, CA 15-3 and HER2-ECD are independent
ndicators for a worse disease free survival and the combination
f both biomarkers is valuable for the identification of high-
isk breast cancer patients [19]. Nevertheless, to the best of our
nowledge, a sensor for the simultaneous determination of CA
5-3 and HER2-ECD has not been reported yet. Therefore, the
urpose of the present work was to develop an electrochemical
mmunosensor for the simultaneous analysis of these biomarkers.
lectrochemical sensors are excellent to be included into point-of-
are devices because of their high selectivity and sensitivity, fast
esponse, simplicity, low cost, easy miniaturization and integra-
ion into automatic systems [7,20,21]. For these reasons, several
lectrochemical immunosensors for CA 15-3 and HER2-ECD detec-
ion were previously developed. However, only a few of these are
ased on screen-printed electrodes [8,22–28], which are miniatur-
zed transducers that allow the development of portable, simple
nd small-size sensors. Some electrochemical immunosensors are
escribed in which CA 15-3 is analyzed together with other cancer
iomarkers such as AFP, CEA, CA 125 or CA 19-9 [25–30]. How-
ver, and as mentioned before, an electrochemical sensor for the
imultaneous detection of CA 15-3 and HER2-ECD has not been
ublished.
In this work, the development of a multiplexed electrochem-
cal immunosensor for the detection of CA 15-3 and HER2-ECD,
ased on dual screen-printed carbon electrodes (bi-SPCE) nanos-
ructured with in situ generated gold nanoparticles, is described.
he applied immunosensing approach is based on a sandwich-type
ssay in which specific capture antibodies for these biomarkers
re immobilized by adsorption onto each nanostructured workingelectrode. The antigen-antibody interaction is sensed using alkaline
phosphatase as label on the detection antibodies and a mixture of
3-indoxyl phosphate with silver ions as substrate [31]. The signal
is the peak current intensity of the enzymatically generated silver
in a linear-sweep voltammogram. Since the signal results from the
metallic silver deposited on the electrode surface at the site of the
enzyme, cross-talk between electrodes is avoided, therefore it is
possible to use the same label for the detection of both biomark-
ers [32,33]. Along the work, different immunoassay strategies and
optimizations were carried out to obtain the highest and most
reproducible analytical signal (i.e. the difference between the sig-
nal for the analytes and the background signal) for both biomarkers.
The developed bi-immunosensor, besides detecting concentration
ranges with clinical importance for both biomarkers, also shows
important characteristics related to Green Analytical Chemistry
[34] such as miniaturization, simplicity, use of low volume of
reagents and sample, multi-analyte determination and possibility
of in situ analysis.
2. Materials and methods
2.1. Equipment
The linear sweep voltammetric measurements and the in situ
electrodeposition of gold nanoparticles were performed using a
Stat 200 bipotentiostat from DropSens. The potentiostat was con-
trolled by DropView (v2.0, DropSens) software, which was  also
used for data acquisition and treatment. Customized dual screen-
printed carbon electrodes (bi-SPCE, DRP-X1110) and a connector
(DRP-BICAST) to interface the bi-SPCE and the bipotentiostat were
supplied by DropSens. The bi-SPCEs, printed on ceramic substrates
(3.4 × 1.0 × 0.05 cm), incorporated two  carbon working electrodes
(elliptic-shaped, A = 6.3 mm2), a silver pseudo-reference electrode
and a carbon auxiliary electrode. The electrochemical cell was
delimited by an insulating layer printed around the electrodes. SEM
images were obtained at the “Centro de Materiais da Universidade
do Porto (CEMUP)” using FEI QUANTA 400 FEG/EDAX Pegasus X4M
equipment.
2.2. Reagents
The immunoreagents for HER2-ECD analysis were purchased
from Sino Biological: anti-human-HER2-ECD rabbit monoclonal
antibody (anti-HER2; capture antibody for HER2-ECD), recombi-
nant human HER2-ECD protein and anti-human-HER2-ECD mouse
monoclonal biotinylated antibody (anti-HER2-bio; detection anti-
body for HER2-ECD). The antibodies for the CA 15-3 assay were
purchased from Fujirebio Diagnostics: anti-human-CA15-3 mouse
monoclonal antibody (anti-CA15-3; capture antibody for CA15-3)
and anti-human-CA15-3 mouse monoclonal biotinylated antibody
(anti-CA15-3-bio; detection antibody for CA 15-3). Human CA 15-3
protein was provided by MyBioSource.com.
The other reagents used throughout the work were: tetra-
chloroauric(III) acid (H[AuCl4]) purchased from Merck; silver
nitrate supplied by alfa Aesar; tris(hydroxymethyl)aminoethane
(Tris),  streptavidin from Streptomyces avidinii conjugated to alka-
line phosphatase (S-AP), 3-indoxyl phosphate disodium salt (3-IP),
-casein from bovine milk, bovine serum albumin (BSA), magne-
sium nitrate hexahydrate and nitric acid (≥65%) obtained from
Sigma-Aldrich.
Working solutions of casein, S-AP and the immunoreagents
were prepared in a 0.1 M Tris-HNO3 pH 7.2 buffer (buffer 1). A
solution containing 1.0 mM 3-IP and 0.4 mM silver nitrate was pre-
pared daily in a 0.1 M Tris-HNO3 pH 9.8 buffer containing 20 mM
Mg(NO3)2 (buffer 2), and stored in opaque tubes at 4 ◦C.  Type I
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aig. 1. Schematic representation of the immunoassay for (A) HER2-ECD and (B) and
A 15-3 on a bi-SPCE-AuNP.
ltrapure water (resistivity = 18.2 M.cm) was used throughout
he work.
.3. Electrodeposition of gold nanoparticles
It is well know that nanostructuration of SPCEs with AuNPs
mproves the biocompatibility of the transducer and facilitates
lectron transfer between the immobilized proteins and the
lectrode surface [35]. In this work gold nanoparticles were elec-
rodeposited, at room temperature, on the surfaces of the carbon
orking electrodes of the bi-SPCEs (bi-SPCE-AuNP) following the
ethod previously reported by Martínez-Paredes et al. [36], since
he AuNPs thus generated have demonstrated a considerable
mprovement of the analytical signal for similar assays [37]. The
anostructuration procedure consisted of dropping 60 L of a
.1 mM [AuCl4]− (in  0.1 M HCl) solution onto the bi-SPCE and apply-
ng a constant potential of −0.7 V during 240s. This was followed
y the application of a constant potential of +0.1 V for 120 s to des-
rb hydrogen formed during the previous step. After rinsing the
i-SPCE-AuNP (Fig. S1) with water they were ready to use.
.4. Immunoassay
The following procedure, summarized in Fig. 1, describes an
ptimized assay. Each working electrode of the bi-SPCE-AuNP was
oated with 4 L of a capture antibody solution (50 g mL−1 anti-
ER2 or 100 g mL−1 anti-CA15-3) and incubated overnight at
◦C. After the overnight incubation, the bi-SPCE-AuNP was washed
sing buffer 1. From this point on all the steps of the immunoassay
ere performed covering both working electrodes with the same
olution. Free surface sites were blocked with a casein solution
60 L, 2% w/v) during 30 min  and afterwards the electrode was
ashed with buffer 1. Then the bi-immunosensor was incubated
or 1 h with 60 L of a mixture (1:1 ratio) of a solution containing
he antigens (HER2-ECD and CA 15-3) and a solution containing the
nti-CA15-3-bio antibody (1 g mL−1) and BSA (1% w/v). After this
tep the sensor was washed with buffer 1 and a 60-L aliquot of a
olution containing the anti-HER2-bio antibody (0.5 g mL−1) and
SA (1% w/v) was placed on the sensor and left to react for 30 min.
inally, after a washing step with buffer 1, 60 L of a 0.5 nM S-AP
olution containing 0.1% BSA (w/v) was dropped on the sensor and
eft to react for 1 h. Then, the electrode was washed with buffer
 and the enzymatic reaction was performed by using a 60-L
liquot of the 1.0 mM 3-IP/0.4 mM AgNO3 solution. The enzymaticdeposition of metallic silver catalyzed by alkaline phosphatase was
already reported previously (Fig. S2) [31]. After 20 min  a linear
voltammogram between −0.02 and 0.4 V at 50 mV s−1 was  recorded
to obtain the electrochemical oxidation current of the enzymat-
ically deposited silver. Since silver was reduced and deposited
on the separate electrodes, no inter-electrode interferences were
observed.
3. Results and discussion
3.1. Immunoassay optimization
The bi-immunosensor was developed based on previous studies
of our group, using an SPCE with one working electrode, of indi-
vidual electrochemical immunoassays for CA 15-3 (unpublished
results) and HER2-ECD [8].
The first approach was  as follows: after incubating the bi-SPCE-
AuNP overnight at 4 ◦C  with the capture antibody solutions (4 L
each, 50 g mL−1 anti-HER2 and 100 g mL−1 anti-CA15-3), the
electrodes were washed with buffer 1. The free surface sites were
blocked with casein (60 L, 2% w/v) during 30 min  and the elec-
trode was  washed with buffer 1. Then the sensor was incubated
for 1 h with 60 L of a mixture (1:1) of a solution containing the
antigens and a solution containing the anti-CA15-3-bio antibody
(2 g mL−1), the anti-HER2-bio antibody (1 g mL−1) and BSA (0.5%
w/v). Another washing step with buffer 1 was performed and 60 L
of a 0.2 nM S-AP solution was  placed on the sensor and left to
react for 1 h. Finally, the sensor was  washed with buffer 2 and the
enzymatic reaction was  performed. The signal was  recorded as indi-
cated in Section 2.4. The results (Fig. S3) showed that the sensor
could distinguish between different HER2-ECD concentrations but
no variation was observed for different CA 15-3 concentrations.
Considering these results, it was  suspected that non-specific
binding of detection antibodies covered up the analytical signal
for CA 15-3. Since only the analytical signal for HER2-ECD was
observed, the results let to believe that the most important non-
specific binding events were related to the anti-HER2-bio antibody.
Therefore, an assay in which the concentration of this antibody
was changed (from 0 to 2 g mL−1) was  carried out (Fig. 2A). The
results of this experiment showed that by decreasing (from 1.0 to
0 g mL−1) the anti-HER2-bio concentration the background sig-
nals also decreased. Furthermore, when no anti-HER2-bio was used
the analytical signal for CA 15-3 was clearly observed, which did not
occur when anti-HER2-bio was used.
In view of this, it was  suspected that the anti-HER2-bio anti-
body interacted with the anti-CA15-3 antibody (capture antibody
for CA 15-3). To verify this the same assay was  performed but in this
case the bi-SPCE-AuNPs were modified with only one of the cap-
ture antibodies, anti-HER2 or anti-CA15-3 (the unmodified working
electrode was  incubated overnight with 4 L of buffer 1). Besides
this, to evaluate the background signal tests without the capture
antibodies were also carried out. The results of this experiment,
presented in Fig. 2B, showed that the peak current intensities are
identical in the absence and presence of anti-CA15-3. So, it was
concluded that anti-HER2-bio did not bind non-specifically to anti-
CA15-3, but its presence did not allow to obtain an analytical signal
for CA 15-3.
To  solve this problem, a new procedure was tested in which
the anti-HER2-bio antibody was added independently, i.e. after the
incubation with the analytes and anti-CA15-3-bio. Furthermore,
the incubation time of this antibody was only 30 min  in order to
minimize non-specific binding. Like this, the assay procedure was
as follows: after blocking the surface with casein, the immunosen-
sor was incubated for 1 h with a 60-L aliquot of a mixture (1:1) of a
solution containing CA 15-3 and HER2-ECD and a solution contain-
Fig. 2. (A) Effect of the concentration of anti-HER2-bio (using anti-CA15-3-
bio  2 g mL−1)  in the absence and presence of the analytes ([HER2-ECD] 0 and
100  ng mL−1 (blue bars -that are the first two  bars for each anti-HER2-bio
concentration-); [CA 15-3] 0 and 50 U mL−1 (red bars -that are the last two bars for
each anti-HER2-bio concentration-). (B) Peak current intensities in the absence of
capture antibodies (no capture Ab) or in the presence of only one of them (anti-HER2
50  g mL−1 or  anti-CA15-3 100 g mL−1)  using anti-CA15-3-bio 1 g mL−1 and  anti-
HER2-bio  1 g mL−1 .  Analyte concentrations: [HER2-ECD] 0 and 100 ng mL−1 (blue
bars -that are the first two bars in each group of four bars-) and [CA 15-3] 0
and 50 U mL−1 (red  bars -that are the last two  bars in each group of four bars-).
Experimental  conditions: anti-HER2 50 g mL−1 ,  anti-CA15-3 100 g mL−1 ,  casein
2%  (w/v), BSA 1% (w/v) in solution of detection antibodies, S-AP 0.2 nM,  3-IP/AgNO3
1.0/0.4 mM.  Average data ± SD are indicated (n = 3). (For interpretation of the refer-
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Fig. 3. Effect of anti-CA15-3-bio and anti-HER2-bio concentrations when anti-
HER2-bio  was  added in an independent step. Analyte concentrations: [HER2-ECD]
0  and 100 ng mL−1 (blue  bars -that are the first two bars in each group of four
bars-)  and [CA 15-3] 0 and 50 U mL−1 (red  bars -that are the second two  bars in
each  group of four bars-). Experimental conditions: anti-HER2 50 g mL−1 ,  anti-
CA15-3  100 g mL−1 ,  casein 2% (w/v), BSA 1% (w/v) in anti-CA15-3-bio solution, BSA
indicated in Table S1. A linear relationship between peak currentnces to colour in this figure legend, the reader is referred to the web  version of this
rticle.)
ng the anti-CA15-3-bio antibody and BSA (1% w/v). Then, after a
ashing step, a 60-L aliquot of an anti-HER2-bio solution con-
aining BSA (0.5% w/v) was added and left for react for 30 min.
n this procedure different concentrations of anti-CA15-3-bio and
nti-HER2-bio were tested (Fig. 3).
By comparing Fig. 3 with Fig. 2A it could be concluded that
he addition of the anti-HER2-bio antibody in an independent
tep resulted in a signal for CA15-3 that is clearly different from
he background signal. For example, for anti-CA15-3-bio and anti-
ER2-bio concentrations of 2 and 1 g mL−1, respectively, in the
ase of Fig. 3, a slight analytical signal for CA15-3 was observed
hile in Fig. 2A no signal for this analyte was  obtained. Com-
aring the anti-CA15-3-bio and anti-HER2-bio concentrations of 2
nd 0.2 g mL−1, respectively, in Fig. 2A, with the anti-CA15-3-bio
nd anti-HER2-bio concentrations of 2 and 0.1 g mL−1, respec-
ively, in Fig. 3, the background signal decreased enormously and
n important analytical signal was obtained for CA15-3. Thus, it was
oncluded that this assay procedure could allow the simultaneous
etection of both biomarkers.
Fig. 3 was also useful to study the effect of the detection-
ntibody concentrations on the analytical signal. As can be seen,0.5% (w/v) in anti-HER2-bio solution, S-AP 0.2 nM,  3-IP/AgNO3 1.0/0.4 mM.  Average
data ± SD are indicated (n = 3). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
the best detection-antibody concentrations are either 1 and
0.5 g mL−1 or  2 and 0.1 g mL−1 (anti-CA15-3-bio and anti-HER2-
bio, respectively). Using these concentrations, an analytical signal
for CA15-3 was  observed and the background signals were lower
than with the other concentrations tested. The 1 and 0.5 g mL−1
antibody concentrations were chosen for further studies because
they provided the highest analytical signals, despite the higher
background signals. Therefore, the concentration of BSA in the
anti-HER2-bio solution was increased, the S-AP concentration was
increased and BSA was added to the S-AP solution. The results of
these experiments are summarized in Fig. 4A. This figure shows
that increasing the BSA concentration in the anti-HER2-bio solu-
tion (see Fig. 3, anti-CA15-3-bio and anti-HER2-bio concentrations
1 and 0.5 g mL−1, respectively) decreased the background signals
for both biomarkers. Moreover, increasing the concentration of S-
AP solution to 0.5 nM and adding BSA (0.1% w/v), the background
signals for both antigens decreased even more. So, finally, the cho-
sen concentrations of both detection antibodies and S-AP were:
anti-CA15-3-bio 1 g mL−1 with BSA 1% (w/v), anti-HER2-bio solu-
tion 0.5 g mL−1 with BSA 1% (w/v) and S-AP 0.5 nM with BSA 0.1%
(w/v).
Once all these conditions were optimized, the effect of the cap-
ture antibody concentration was  evaluated. Fig. 4B summarizes the
results using different concentrations of capture antibodies. For
the sake of economy and sensitivity, the concentrations chosen as
optimal for anti-CA15-3 and anti-HER2 were 100 and 50 g mL−1,
respectively.
3.2. Analytical characteristics of the immunosensor
Under the optimized conditions (indicated in Section 2.3.2.),
the response of the dual immunosensor to different concentra-
tions of HER2-ECD and CA 15-3 was evaluated (concentrations
between 0 and 100 ng mL−1 for  HER2-ECD and between 0 and
100 U mL−1 for CA 15-3). The figures of merit of the method areintensity and antigen concentration was  found between 9.8 and
50 ng mL−1 for HER2-ECD and between 17 and 70 U mL−1 for CA
15-3 according to the following equations (Fig. 5): ip (A) = 0.375
Table 1
Comparison of analytical properties of recent electrochemical immunosensors for CA15-3 and HER2-ECD detection.
Biomarker Construction Detection Concentration range LOD Ref.
CA 15-3, HER2- ECD Sandwich-type assay for simultaneous
determination immobilizing capture Abs
on bi-SPCE- AuNPs. Sandwich-type assay.
AP as label.
LSV CA 15-3: 0–70 U mL−1;
HER2-ECD: 0–50 ng mL−1
CA 15-3: 5.0 U mL−1;
HER2-ECD: 2.9 ng mL−1
This work
HER2-ECD. Label-free using affibody immobilized on
AuNPs/GSPE as bioreceptor.
EIS 0–40 ng mL−1 6.0 ng mL−1 [38]
HER2-ECD Sandwich-type assay on SPCE-AuNPs
immobilizing capture Ab by adsorption. AP
as  label.
LSV 15–100 ng mL−1 4.4 ng mL−1 [8]
HER2-ECD Sandwich-type assay coupling capture Ab
to protein A modified magnetic beads.
SPCE as transducer and AP as label.
DPV 0–15 ng mL−1 6 ng mL−1 [23]
HER2-ECD Sandwich-type assay using Nanobodies.
SPCE as transducer and HRP as label.
Amperometry 1–200 g mL−1 1 g mL−1 [22]
HER2-ECD Label free. Capture Ab attached to iron
oxide nanoparticles which are laid over a
gold electrode.
DPV 0.01–10 ng mL−1;  10–100
ng  mL−1
0.995 pg mL−1 [39]
HER2-ECD Sandwich-type assay. Capture Ab
immobilized on AuNPs-modified glassy
carbon electrode. For detection a conjugate
of hydrazine-AuNP-aptamer is used.
SWSV 0.1 pg mL−1–10  ng mL−1 0.037 pg mL−1 [40]
HER2-ECD Label free. Capture Ab immobilized on
AuNPs/HDT/AuNPs@MWCNT-CIL
electrode.
EIS 10–110 ng mL−1 7.4 ng mL−1 [41]
CA 15-3 Nanoporous gold/graphene modified
glassy carbon electrode. Sandwich type
assay using HRP-encapsulated liposomes
as labels.
DPV 2·10−5–40  U mL−1 5·10−6 U  mL−1 [42]
CA 15-3 Label free. Capture Ab attached onto
N-doped graphene sheets and then
immobilizing on a glassy carbon.
DPV 0.1–20 U mL−1 0.012 U mL−1 [43]
CA 15-3 Sandwich-type assay. Capture Ab
immobilized on graphene-oxide-modified
gold  electrode. For detection
Ab/MWCNT/ferritin bioconjugated is used.
DPV 0.05–100 U mL−1 0.009 U mL−1 [44]
CA 15-3 Label free. Capture Ab immobilized on a
glassy carbon electrode modified with
ferrocene/electrochemically reduced
graphene oxide/electrochemically
generated AuNPs composited used as
immobilizin platform and signal probe.
DPV 0.05–2.0 U mL−1;  2.0–25.0
U  mL−1
0.015 U mL−1 [45]
CA 15-3 Sandwich-type assay immobilizing capture
Ab on glassy carbon electrode modified
with AuNPs functionalized graphene.
Detection Ab adsorbed on grafting
polystyrene-based polymer chains with
pendant Ru(II) luminophore on the surface
of palladium nanocages is used for
detection.
ECL 0.01–120 U mL−1 0.003 U mL−1 [46]
CA 15-3 Sandwich-type assay. Capture Ab labelled
graphene oxide immobilized on SPCE.
Peroxidase-like magnetic silica
nanoparticles/graphene oxide/detection
Ab composites are used for detection.
DPV 10−3 −  200 U mL−1 2.8·10−4 U  mL−1 [24]
CA 15-3, CA 125, CEA Sandwich-type assay for simultaneous
determination immobilizing capture Ab on
graphene modified SPCE with three WEs.
Mesoporous platinum NPs as label.
DPV CA 15-3: 0.008–24 U mL−1 CA 15-3: 0.001 U mL−1 [25]
CA 15-3, CA 125, CEA Sandwich-type assay for simultaneous
determination immobilizing capture Ab on
a  AuNPs/graphene modified SPCE with
three WEs. A conjugate AP/detection Ab/Au
clusters/graphene is used for detection.
LSV CA 15-3: 5·10−3–50  U mL−1 CA  15-3: 1.5·10−3 U  mL−1 [26]
CA 15-3, CA 125, CA
19-9
Sandwich-type assay for simultaneous
determination immobilizing capture Ab on
magnetic beads and using PAMAM
dendrimer-metal sulfide QD as
distinguishable label. An in situ formed
mercury drop electrode on a glassy carbon
as WE.
SWSV CA 15-3: 0.01–50 U mL−1 CA 15-3: 0.005 U mL−1 [29]
WE:  working electrode; LSV: linear sweep voltammetry; DPV: differential pulse voltammetry; SWSV: square wave stripping voltammetry; EIS: electrochemical impedance
spectroscopy; ECL: electrochemiluminescence; GSPE: graphite screen-printed electrode; HDT: 1,6-hexanedithiol; MWCNT: multiwalled carbon nanotube; CIL: carbon ionic
liquid;  AP: alkaline phosphatase; QD: quantum dots; CEA: carcinoembryonic antigen; NP: nanoparticles.
Fig. 4. (A) Effect of the concentration of S-AP and the use of BSA in the S-AP solution
(using  anti-HER2 50 g mL−1 and anti-CA15-3 100 g mL−1).  (B) Effect of the con-
centration  of the capture antibodies. Analyte concentrations tested: [HER2 ECD] 0
and 100 ng mL−1 (blue  bars -that are the first two  bars in each group of four bars-)
and [CA 15-3] 0 and 50 U mL−1 (red  bars -that are the second two bars in each group
of  four bars-). Experimental conditions: casein 2% (w/v), anti-CA15-3-bio 1 g mL−1
with  BSA 1%, anti-HER2-bio solution 0.5 g mL−1 with  BSA 1% (w/v) (independent
step),  S-AP 0.2 nM with BSA 0.1% (w/v), 3-IP/AgNO3 1.0/0.4  mM.  Average data ± SD
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Fig. 5. Simultaneous determination of HER2-ECD and CA 15-3 using the developed
immunosensor.  Linear sweep voltammograms (−0.02 to +0.4 V) for the analysis of
(A) HER2-ECD and (B) CA 15-3; [HER2-ECD] (I to VI): 0, 10, 20, 30, 50, 100 ng mL−1;
[CA  15-3] (I to VI): 0, 20, 40, 50, 70, 100 U mL−1 .  (C) Calibration curves obtained
for  HER2-ECD (from 0 to 50 ng mL−1)  and CA 15-3 (from 0 to 70 U mL−1);  inset: the
peak  current intensity values obtained for HER-ECD (from 0 to 100 ng mL−1)  and
CA 15-3 (from 0 to 100 U mL−1).  Error bars correspond to the standard deviation
of  3 measurements. Experimental conditions: anti-HER2 50 g mL−1 ,  anti-CA15-3
both markers in the range of concentration with clinical impor-re indicated (n = 3). (For interpretation of the references to colour in this figure
egend,  the reader is referred to the web version of this article.)
HER2-ECD] (ng mL−1) + 4.00; R = 0.998, n = 5; ip (A) = 0.157 [CA
5-3] (U mL−1) + 1.57; R = 0.998, n = 5. The limits of detection (LOD)
nd limits of quantification (LOQ) were calculated from the cal-
bration plot using the equations LOD = 3 sb/m  and LOQ = 10 sb/m,
here sb is  the standard deviation of the intercept and m is the
lope of the calibration plot. In the case of HER2-ECD, the LOD was
ound to be 2.9 ng mL−1 while  for CA 15-3, the LOD was 5.0 U mL−1.
he obtained LOQs were 9.8 ng mL−1 and 17 U mL−1 for HER2-ECD
nd CA 15-3, respectively. Considering the cut-off values for HER2-
CD 15 ng mL−1 and for CA 15-3 25 U mL−1, the LOQs are clearly
ower than the cut-off values, so the developed bi-immunosensor
ould be useful in the diagnostic, treatment and follow-up of breast
ancer patients. The precision of the method for the analysis of
oth biomarkers is also adequate because Vx0 ≈ 5%. Although elec-
rochemical immunosensors were previously published for the
ndividual or simultaneous (together with other cancer biomark-
rs, but not including the CA15-3 & HER2-ECD pair) detection of
A 15-3 and HER2-ECD, in several cases achieving lower LODs
han in the present work (Table 1), the simplicity of the proposed
i-immunosensor makes it attractive, even more since the concen-
rations it covers is in the clinical useful range. Furthermore, the
mmobilization of the capture Ab by simply adsorption obviates the
eed of use cross-linkers, polymers or self-assembly monolayers,
educing the operation complexity and assay cost.100  g mL−1 ,  casein 2% (w/v), anti-CA15-3-bio 1 g mL−1 with BSA 1% (w/v), anti-
HER2-bio  solution 0.5 g mL−1 with BSA 1% (w/v), S-AP 0.5 nM with BSA 0.1% (w/v),
3-IP/AgNO3 1.0/0.4 mm.
4. Conclusions
The current trends in analytical chemistry are focused on devel-
oping simple and in situ analysis devices. Moreover, it is still an
important challenge to be able to simultaneously determine sev-
eral analytes with the same device. Therefore, in this work the
first multiplexed electrochemical immunosensor for the simulta-
neous detection of two  breast cancer biomarkers (CA 15-3 and
HER2-ECD) was  developed. Several aspects of the immunoassay
were studied in order to achieve an immunosensor able to detecttance. An immunosensor with limits of detection of 2.9 ng mL−1
for HER2-ECD and 5.0 U mL−1 for CA 15-3 was  achieved. Consider-
ing the cut-off values, 15 ng mL−1 and 25 U mL−1 for HER2-ECD and
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[A 15-3 respectively, the usefulness that this immunosensor could
ave in clinical analysis is clear. The possibility to simultaneously
nalyze two biomarkers increases the sensor’s utility. Moreover,
his sensor can be included in a portable and ready-to-use device
ue to the use of SPE as transducer. Thus, this sensor could be a
alue tool for a rapid and non-invasive screening breast cancer test
nd control of these biomarkers in breast cancer patients under
reatment.
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